Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313612 · ClinicalTrials.gov registry record · Phase 2
Oxaliplatin and Topotecan in Advance Ovarian Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT00313612: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00313612 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00313612, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving oxaliplatin together with topotecan works in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as oxaliplatin and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Interventions
- DRUG oxaliplatin
- DRUG topotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2006-01 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00313612
The ClinicalTrials.gov registry entry for NCT00313612 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which oxaliplatin is the first listed.
NCT00313612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00313612 about?
NCT00313612 is a clinical study titled "Oxaliplatin and Topotecan in Advance Ovarian Cancer". This phase II trial is studying how well giving oxaliplatin together with topotecan works in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as oxaliplatin and topotecan, work in different ways to stop the growth...
What is the current status of trial NCT00313612?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2006-01. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00313612?
The interventions under investigation include: oxaliplatin (DRUG), topotecan (DRUG).
Who is sponsoring clinical trial NCT00313612?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.